Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Andros Pharmaceuticals Co. Ltd. manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners and an equal number of distinct art units. This indicates that each active case is undergoing review by a different examiner in a separate administrative department. The distribution suggests that the company's pharmaceutical innovations are being evaluated across different specialized units within the USPTO.
ALSTRUM ACEVEDO, JAMES HENRY is the busiest examiner for the company, holding 1 pending office action. With 2 total pending office actions, the company is interacting with multiple examiners. This requires coordinating prosecution across separate art units within the biotechnology sector. For the practitioner, the lack of concentration means that each case requires a unique approach tailored to the specific technical expectations and procedural nuances of the assigned examiners. Maintaining a dual-track strategy is essential to advancing these distinct matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALSTRUM ACEVEDO, JAMES HENRY | 1 | 40.8% | -19.9% |
| TIEN, LUCY MINYU | 1 | 59.1% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18373612 | TOPICAL DELIVERY COMPOSITIONS COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | TIEN, LUCY MINYU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18373612 | TOPICAL DELIVERY COMPOSITIONS COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | TIEN, LUCY MINYU | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18426213 | Topical anesthetic agent-clay composite compositions | ALSTRUM ACEVEDO, JAMES HENRY | 1622 | §103 | Final Rejection | 41d | Pending | Jan 29, 2024 |
| 18373612 | TOPICAL DELIVERY COMPOSITIONS COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | TIEN, LUCY MINYU | 1612 | §102§103 | Non-Final OA | — | Pending | Sep 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAndros Pharmaceuticals Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
James Henry Alstrum Acevedo has the most, with 1 of Andros Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
